Trial Profile

A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alvelestat (Primary)
Indications Alpha 1-antitrypsin deficiency
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms ATALANTa

Most Recent Events

22 May 2024 Results assessing the safety/tolerability and the mechanistic effect of oral alvelestat in subjects with Pi*ZZ, Pi*SZ, or Pi*Null AATD, presented at the 120th International Conference of the American Thoracic Society.
22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society
08 Dec 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com